Ga-68 DOTATATE Positron Emission Tomography Computed Tomography Findings in Patients with Neuroendocrine Tumor Suspicion

Nöroendokrin Tümör Şüphesi Olan Hastalarda Ga-68 DOTATATE Pozitron Emissiyon Tomografisi/Bilgisayarlı Tomografi Bulguları

Çiğdem Soydal, Elgin Özkan, Evrim Bali, Özlem N. Küçük, Metin K. Kır

Aim: We aimed to retrospectively evaluate the outcome of patients with suspected neuroendocrine tumor (NETs) who underwent Ga-68 DOTATATE Pozitron Emission Tomography/Computed Tomography (PET/CT) imaging and to describe the value of Ga-68 DOTATATE PET/CT in the detection of NETs.

Material and Method: Ga-68 DOTATATE PET/CT images of 35 patients (26M; 9F, mean age; 45.2±5.4 years) with suspected NET were analyzed retrospectively. Suspicion of NET was due to clinical symptoms (n:12), elevated biochemical markers (n:19) and/or radiological findings (n:13). Clinical/imaging follow-up and/or histopathological confirmation was used as reference standard.

Results: Based on the reference standard 13 of 35 patients had NET. Ga-68 DOTATATE PET/CT was positive in 12 out of 13 patients and it was false negative in 1 patient. Pancreas was the commonest site of the primary tumor. Ga-68 DOTATATE was TP(true pozitive), FP (False Positive), TN (True Negative) and FN (False Negative) in 12, 2, 20 and 1, patients respectively. Sensitivity, specificity, Pozitive Pedictive Value (PPV), Negative Pedictive Value (NPV), and accuracy of Ga-68 DOTATATE PET/CT was calculated as 85%, 95%, 92%, 90% and 91%, respectively.

Conclusion: Ga-68 DOTATATE PET/CT has a high accuracy in the detection of suspected NET. It can be used for searching possible NET in patients with suspicion.

Key Words: Neuroendocrine Tumor, Ga-68 DOTATATE, PET/CT

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms arising form neuroendocrine cells (1). Although most of the NETs originates from gastroenteropancreatic tract, endocrine glands such as thyroid, pituitary and adrenal, respiratory tract and skin could be the primary location of NETs. In addition to their variable biological behavior, small size and diverse locations of most NETs make the diagnosis difficult. Typical symptoms are called as carcinoid syndrome, however they are not specific for NETs diagnosis. Moreover, carcinoid syndrome is not seen in most cases and clinical symptoms are usually nonspecific in these cases. Fifty-70% of NETs do not produce any specific biochemical markers (2). Chromogranin A (CgA) is nonspecific marker and has limited sensitivity and specificity (3). Conventional imaging tools and endoscopic techniques might be non-diagnostic or negative for diagnosis of NETs (4).
Radiolabeled (with Tc-99m, In-111 or Ga-68) somatostatin analogs have been used for imaging of NETs. Especially, positron emission tomography (PET)/computed tomography (CT) with Ga-68 labeled DOTA-peptides have been shown superior to conventional methods as well as In-111 octreotide scintigraphy (5-6). According to these encouraging results, PET/CT with Ga-68 labeled DOTA-peptides has been performed to search possible NET in patients with clinical, biochemical or radiological suspicion of NET. In this study, we aimed to evaluate retrospectively the outcome of patients with suspected NETs who underwent Ga-68 DOTATATE PET/CT imaging and to describe the value of Ga-68 DOTATATE PET/CT in the detection of NETs.

2. Material and Methods

2.1 Patients

Thirty-five (26M; 9F, mean age: 45.2±5.4 years) patients who underwent Ga-68 DOTATATE PET/CT for clinical/biochemical or radiological suspicion of NET were included in the study. Twelve patients had symptoms that could be related to NET, 19 patients had elevated biochemical markers such as CrA or gastrin and 13 patients had radiological findings. Some of patients presented with more than one of the findings. Histopathological confirmation (2 FNAB of pancreas, 1 pancreatic resection, 1 transbronchial lung biopsy, 1 endoscopic stomach and 1 duodenal biopsy) was used for every patient who was ethically and technically suitable. A combination of clinical, biochemical and imaging follow-up at least 6 (mean: 24.6±12.4 months) months has been preferred as reference standard at the rest of the patients (n=29).

2.2 Ga-68 DOTATATE PET/CT imaging

PET/CT images were acquired with Discovery ST PET/CT scanner (General Electric, Milwaukie, Wisconsin, USA). Synthesis of Ga-68 DOTATATE was performed by automated synthesis unit (Scintomics GmbH, Fürstenfeldbruck, Germany). Images were obtained approximately 1 hour after an intravenous injection of approximately 100 MBq of Ga-68 DOTATATE. An oral contrast agent was given to patients with abdominal lesions in conventional imaging methods. Whole body PET/CT imaging was performed while patients were in supine position from the vertex to the mid thighs. Computed Tomography (CT) image was obtained from the integrated Positron Emission Tomography/Computed Tomography PET/CT scanner with the use of a standardized protocol involving 140 kV, 70 mA, a tube rotation time of 0.5 s per rotation, a pitch of 6 and a section thickness of 5 mm. Immediately after the CT part, Positron emission tomography images were acquired for 5 minutes per bed position. PET images were reconstructed using non-contrast CT data for attenuation correction. PET/CT images were evaluated visually for regions of pathologically increased tracer uptake that could not be accepted as normal physiologic activity.

2.3 Statistical Analysis

Data were summarized as mean±standard deviation. Sensitivity, specificity, PPV, NPV and accuracy of Ga-68 DOTATATE PET/CT were calculated. All statistical analyses were performed using SPSS computer statistical software (version 16.0; SPSS, Chicago, Illinois).

3. Results

The most common clinical symptom was diarrhea with 6 patients (17%). Eight (22%) patients had elevated CrA and 4 (11%) patients Gastrin levels. Radiological suspicion of NET was due to pancreatic masses in pancreas Magnetic resonance imaging (n=13). In our study the most common indication of Ga-68 DOTATATE PET/CT is elevated blood biochemical marker levels. PET/CT was FN in 8 and FP in 1 out of 13 patients. Details of patient characteristics were demonstrated in Table 1.

Ga-68 DOTATATE was normal in 21 patients. Based on the reference standard Ga-68 DOTATATE PET/CT was FN in one patient who was diagnosed as VIPoma with typical clinical presentation, detection of millimetric pancreatic lesion in the follow-up MRI and relief of symptoms with long acting somatostatin analog treatment. Details of FN and FP findings were demonstrated in Table 2. Based on

### Table 1: Details of patient characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>9 (25)</td>
</tr>
<tr>
<td>Male</td>
<td>26 (75)</td>
</tr>
<tr>
<td>Reason ofSuspicion</td>
<td></td>
</tr>
<tr>
<td>Clinical symptoms</td>
<td>12 (34)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>6 (17)</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>3 (9)</td>
</tr>
<tr>
<td>Other</td>
<td>3 (9)</td>
</tr>
<tr>
<td>Biochemical markers</td>
<td></td>
</tr>
<tr>
<td>CrA</td>
<td>19 (54)</td>
</tr>
<tr>
<td>Gastrin</td>
<td>4 (10)</td>
</tr>
<tr>
<td>Neuron specific enolase</td>
<td>4 (10)</td>
</tr>
<tr>
<td>Insulin</td>
<td>3 (9)</td>
</tr>
<tr>
<td>Radiological Findings</td>
<td>13 (37)</td>
</tr>
</tbody>
</table>

### Table 2: Details of False Positive and False Negative Findings

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Age</th>
<th>Gender</th>
<th>Indication for Ga-68 DOTATATE PET/CT</th>
<th>Gold standard</th>
<th>Ga-68 DOTATATE PET/CT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>57</td>
<td>M</td>
<td>18 mm suspected mass in pancreatic tail</td>
<td>Ectopic spleen</td>
<td>FP</td>
</tr>
<tr>
<td>2</td>
<td>36</td>
<td>F</td>
<td>Elevated CrA levels and chronic diarrhea</td>
<td>VIPoma</td>
<td>FN</td>
</tr>
<tr>
<td>3</td>
<td>46</td>
<td>F</td>
<td>Elevated CrA levels</td>
<td>Duedonitis</td>
<td>FP</td>
</tr>
</tbody>
</table>
the reference standard 13 of 35 patients had neuroendocrine tumor. Ga-68 DOTATATE PET/CT was positive in 12 of 13 patients and it was false negative in 1 patient. Pancreas was the commonest site of primary tumor (n=7, Figure 1), the second site was the small bowel (n=6). Ga-68 DOTATATE PET/CT was TP in 6 out of 7 patients with pancreatic mass. Additionally it was detected peripancreatic lymph node metastases in 1 patient. Ga-68 DOTATATE PET/CT was TP in 6 out of 7 patients with pancreatic mass. Ga-68 DOTATATE PET/CT was FP in 2 patients and histopathological examinations have resulted as ectopic spleen tissue (Figure 2) in pancreas and duodenitis in these patients. Sensitivity, specificity, PPV, NPV and accuracy of Ga-68 DOTATATE PET/CT were calculated as 85%, 95%, 92%, 90% and 91%, respectively.

4. Discussion

Today PET/CT with Ga-68 DOTA-peptides has been used for evaluation of NET patients (7-9). High accuracy of Ga-68 DOTA-peptide PET/CT in the detection of NET lesions has been reported in different studies (7-11). Presence of increased uptake areas other than physiological uptake sites demonstrates the lesions over-expressing Somatostatin Receptor (SSTR). Although exclusion of inflammatory causes of increased uptake is done, final diagnosis of NET should be confirmed by pathological examination. Despite of its widely availability, relatively non-invasive nature and advantages of whole body screening, routine usage of Ga-68 DOTA-peptide PET/CT in the suspicion of NET has not widely been accepted.

This study has been established to evaluate the outcome of patients with suspected NETs who underwent Ga-68 DOTATATE PET/CT imaging. In our study the most common indication of Ga-68 DOTATATE PET/CT is elevated blood biochemical marker levels. PET/CT was TN in 8 and FP in 1 out of 13 patients. These results support the data about low sensitivity of Cr-A in the diagnosis of NET (12). Elevated Cr-A levels can be detected in several malignant and benign conditions such as cardiovascular, gastrointestinal, pulmonary, rheumatologic and endocrine disorders (13-16). Additionally a group of medications mostly commonly proton pump inhibitors may affect serum Cr-A levels (17). In 3 patients those have accompanying radiological findings PET/CT was True Positive (TP). For these reasons Ga-68 DOTATATE PET/CT seems to be more helpful in patients with both elevated biochemical markers and radiological findings.

Ga-68 DOTATATE PET/CT was FP and FN in 2 and 1 patient, respectively. Histopathological examinations have resulted as ectopic spleen tissue in pancreas and duodenitis in FP patients. Ectopic spleen tissue in pancreas is not uncommon condition and it can mimic pancreatic NET (17, 18). Presence of ectopic pancreatic tissue should be considered in suspected patients and Tc-99m Colloid scintigraphy may help to differential diagnosis (18). Another common false positive Ga-68 DOTA-peptide uptake cause is inflammatory changes (19). Endoscopic confirmation in patients who are suitable or repeat of imaging after anti-inflammatory/antibiotics therapy can eliminate FP uptake. Detection rate of VIPoma with Ga-68 DOTA-peptide PET/CT has been reported high (20). Contrarily in our series we had only one patient with VIPoma and Ga-68 DOTATATE PET/CT was FN in that patient. In our patient, possible explanation for this FN finding could be spatial resolution limitation of PET due to millimetric dimension of pancreatic lesion.

Major limitations of present study are the small number of patient population and retrospective design. However recent literature has a few studies on the role of Ga-68 DOTA-peptide PET/CT in the management of patients with neuroendocrine tumor suspicion. For this reason we thought results of this series could be worth to share.
5. Conclusion

Ga-68 DOTATATE PET/CT has a high accuracy in the detection of suspected neuroendocrine tumor. Although FP and FN findings are rare, inflammatory processes and millimetric tumors should be considered. In selected patients, Ga-68 DOTATATE PET/CT could be used to search possible neuroendocrine tumor focus and it is more successful in patients with elevated tumor marker and radiological findings.

REFERENCES


